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Abstract 23
Drug repurposing, identifying novel indications for drugs, bypasses common drug 24 development pitfalls to ultimately deliver therapies to patients faster. However, 25 most repurposing discoveries have been led by anecdotal observations (e.g. 26
Viagra) or experimental-based repurposing screens, which are costly, time-27 consuming, and imprecise. Recently, more systematic computational 28 approaches have been proposed, however these rely on utilizing the information 29 from the diseases a drug is already approved to treat. This inherently limits the 30 algorithms, making them unusable for investigational molecules. Here, we 31 present a computational approach to drug repurposing, CATNIP, that requires 32 only biological and chemical information of a molecule. CATNIP is trained with 33 2,576 diverse small molecules and uses 16 different drug similarity features, 34 such as structural, target, or pathway based similarity. This model obtains 35 significant predictive power (AUC = 0.841). Using our model, we created a 36
repurposing network to identify broad scale repurposing opportunities between 37 drug types. By exploiting this network, we identified literature-supported 38
repurposing candidates, such as the use of systemic hormonal preparations for 39 the treatment of respiratory illnesses. Furthermore, we demonstrated that we can 40 use our approach to identify novel uses for defined drug classes. We found that 41 adrenergic uptake inhibitors, specifically amitriptyline and trimipramine, could be
Introduction 48
With over $800 million spent bringing a single drug to market over the course of 49 15 years, drug development has remained a costly and time-consuming affair 1 . In 50 response, there has been an increase in interest in drug repurposing, the 51 identification of novel indications for known, safe drugs. Successes in this area 52 have been seen in the past, most notably in sildenafil (e.g. Viagra), which was 53 originally intended to treat hypertension and angina pectoris but was later 54 repurposed to treat erectile dysfunction. Other examples of compounds 55 repurposed for new therapeutic applications include minoxidil 2 and raloxifene 3 , 56
which are now used to treat androgenic alopecia and osteoporosis, respectively. 57
However, most of these repurposing opportunities were discovered through 58 inefficient approaches including anecdotal observations or hypothesis-driven 59 investigations, and a more efficient approach could lead to many more 60 repurposing opportunities. 61 62 Computational approaches for repurposing drugs are appealing in that they can 63 be systematically and quickly applied to many drugs at a low cost compared to 64 their experimental counterparts. One computational approach that has proven to 65 be invaluable in other areas of the drug development pipeline is machine 66 learning. Machine learning is the use of computational algorithms to learn from 67 available data to make novel predictions and gain new insight. Using this 68 technique, one can create unbiased algorithms to match seemingly disparate 69 drugs by comparing their common features 4 , such as clinical indication, toxicity 70 profile 5 or therapeutic target 6,7 . Previously, our lab used a 'similarity' approach, 71 leveraging the principle that similar drugs tend to have similar characteristics, to 72 predict a drug's target by investigating the known targets of other drugs that were 73 predicted to be "similar" to the investigated drug based on shared features 6 . We 74 found that DRD2, a dopamine receptor, was the predicted target for the 75 compound ONC201. After identifying and experimentally validating this target, 76 clinical trials were shifted to focus on gliomas, which are now successfully 77 completing phase two trials at the time of this publication 8 . The approach of 78 leveraging drug similarity could immensely aid drug repurposing efforts with the 79 appropriate data. 80
81
Others have successfully used this 'similarity' approach to repurpose drugs and 82 demonstrated high predictive power when tested against FDA approved drug-83 diseases 9 . However, these methods have primarily linked drugs together using a 84 disease-centric approach instead of using features related to the drug itself (i.e. 85 drug-centric). These repurposing opportunities are identified by predicting 86 diseases similar to the diseases a drug is already known to treat. Disease 87 similarities can be based on semantic, pathophysiological, or clinical similarities 88 related to the drug's clinical indication. For example, PREDICT, a repurposing 89 method developed by Gottlieb et al. 10 , exploits the semantic similarity of disease 90 terms as a form of disease-disease similarity. Such approaches, while reliable, 91 limit the scope of the repositioning effort in several ways. First, the vast majority 92 of small molecules never reach clinical approval and would be overlooked in this 93 type of analysis. Second, the use of a disease-centric approach biases 94 repurposing predictions toward exclusively similar clinical diseases (i.e.: cancer 95 drugs to other cancer types) 11 . We postulated that using solely drug information, 96 such as chemical and biological features, would be a more effective and broader 97 approach to drug repurposing. 98
99
Here, we propose a novel approach to drug repurposing, which operates by a 100 platform we call, Creating A Translational Network for Indication Prediction 101 and those not known to share an indication (Figure S2-5). For example, we 141 found that drug pairs with a shared clinical indication, according to their listed 142 DrugBank indications, tended to have significant overlap in targets (D-statistic = 143 0.168, p-value < 0.001, Figure S2A ). The feature which best discriminated 144 between drug pairs that shared a clinical indication versus drug pairs that do not 145 was the similarity between the KEGG pathways that each drug's targets are 146 involved in (D-statistic = 0.241, p < 0.001, Figure S4C ). Pathway similarity was 147 calculated as the Jaccard Index between the KEGG pathways that contain each 148 drug's gene targets (Methods). The difference in effect size between the target 149 similarity and the pathway similarity (D-statistic= 0.168 vs 0.241, respectively) 150
indicates that the drugs do not necessarily have to target the same exact genes, 151 but rather the same biological pathway, in order to share a clinical indication. 152
Additionally, we found that drug pairs that share an indication had a more similar 153 chemical structure than drug pairs that did not share an indication (D-statistic = 154 0.105, p-value < 0.001, Figure S5A ). Overall, these features seem to indicate 155 sufficient power in differentiating drugs that share and do not share indications, 156 which we hypothesized can then be leveraged to create a predictive model. 157
158

Drug pairs that share indications can be predicted by model 159
Using these diverse drug properties as features we trained a Gradient Boosting 160 model to predict if two drugs share a clinical indication. A Gradient Boosting 161 model showed superior results when compared with other algorithms (Methods, 162 Table S2 ). The model output is a drug similarity score (hereby referred to as a 163 "CATNIP score"), which allows us to classify drug pairs that share clinical 164 indications. We performed a 5-fold cross-validation analysis and achieved 165 significant predictive performance with an area-under-the-receiver-operator curve 166 (AUC) of 0.841 (Figure 2A) . We confirmed the statistical significance of our 167 model with a precision-recall curve (PRC) because of the class imbalance in our 168 dataset between drug pairs that share indications against those that do not 169 
Network clusters identify drugs with similar clinical characteristics 187
We constructed a repurposing network by calculating a CATNIP score for all 188 possible drug pairs found within DrugBank, and assigning the drugs as nodes 189 and the CATNIP score as the edge weight. We pruned the network using a cut-190 off value of 7.4 for the CATNIP scores ( Figure 2B) , which included 792 different 191 drug pairs. This cut-off is equivalent to a predicted probability of >99% to share 192 an indication and allowed for a balance between confidence within our 193 predictions and drug diversity and availability. 194
195
We hypothesized that drugs sharing at least one indication would cluster together 196 in our network. To confirm this theory, we classified each drug per its 1st order Metabolism') and the fibrates, fenofibrate and bezafibrate (ATC classification: 205
'Cardiovascular system'). These two clustered ATC classifications were 206 connected by a high (7.42) CATNIP score between bezafibrate and pioglitazone, 207 an antidiabetic drug; a relationship driven by the shared targeting of PPARa and 208
PPARg resulting in the improvement of lipid and glucose metabolism. Bezafibrate 209 has shown efficacy in the treatment of Type 2 Diabetes in numerous 210 retrospective and pre-clinical studies, including Phase 2 trials 19-21 , however is still 211 not an approved antidiabetic. The identification of bezafibrate as a potential 212 diabetes treatment is a key example of how CATNIP can be used to identify 213 repurposing opportunities. 214
215
We reasoned that the connections between ATC classifications across all the 216 drug clusters could provide additional aid for drug repurposing purposes. Using 217 the pruned network (CATNIP Score > 7.4), we collected all the scores between 218 drugs of differing ATC classifications. From this collection, we were able to 219 determine the median score associated between each pair of ATC 220 classifications. The ATC classifications with the highest median CATNIP scores 221 had literature support for numerous repurposing efforts between them ( Table 1) . 222
For example, drugs with the ATC classifications of "Respiratory System" and 223 "Systemic Hormonal Preparations, excluding sex hormones and insulins" were 224 strongly connected to each other (7.97 median CATNIP score). This connection 225 was driven by highly scored pairs of drugs including rimexolone to mometasone 226 (8.31 CATNIP score) and prednisone to triamcinolone (8.13 CATNIP score). 227
These connections are supported by the fact that hormonal agents like 228 glucocorticoids and beta adrenergic agonists have been used for decades to 229 relax the airway musculature in patients with reactive airways disease and 230 chronic obstructive pulmonary disease 22 . Interestingly, our analysis identified 231 glucagon, a peptide hormone that increases blood glucose levels, as a candidate 232 for "Respiratory System" repurposing and this use already has clinical 233 support 23,24 . Additionally, drugs classified as "Respiratory System" and 234 "Dermatological" were also observed to be highly associated because of 235
interactions such as the one between ciclesonide and hydrocortisone (8.43 236 CATNIP score). Ciclesonide and hydrocortisone do in fact share a clinical 237 indication, "Asthma Bronchial", giving added confidence to our findings. These 238 types of network observations are important in laying the groundwork for 239 suggesting novel clinical repurposing strategies for FDA-approved drugs. 240
241
CATNIP identifies novel disease areas for drug classes 242
We investigated the ability to leverage CATNIP scores to identify repurposing 243 opportunities by evaluating specific drug classes. Drug classes are predefined in 244
DrugBank. In order to identify actionable repurposing possibilities, we narrowed 245 this list down to 50 classes containing inhibitors, antagonists, or agonists of 246 specific gene or protein families. We focused our attention on specific disease 247 areas that are attractive for drug repurposing opportunities, due to a lack of 248 current treatments or high rates of acquired resistance. The specific disease 249 areas were: "mental disorders", "neurological diseases", "diabetes", and "cancer" 250 (cancer was further divided into specific cancer types due to the large variance in 251 disease pathology between types, Methods). We hypothesized that CATNIP 252 scores could be used to identify specific drug classes that would be efficacious 253 for a new disease area. For each drug class and disease area, we found the 254 statistical difference in the CATNIP score distribution between two sets of drug 255 pairs. The first set included pairs that had one drug within the drug class and the 256 other drug approved for the disease in question, while the other set included drug 257 pairs that had one drug within the drug class and the other drug not approved for 258 the disease in question (Methods). We compared the effect size, estimated by 259 the Wilcoxon location shift, for all drug class-disease pairs that had a significant 260 difference in distribution compared to drug class-non-disease pairs (FDR < 0.1, 261 Figure 3A -B, Figure S7-8) . By using CATNIP scores, we found that many well-262 known drug class-diseases associations could be recovered. For example, "muscarinic antagonists" were highly ranked for "neurological diseases" and 264 many such agents are FDA-approved for this indication 25 . In addition, we found 265 that "kinase inhibitors" were closely associated with the treatment of cancer and 266 "dopamine antagonists" for the treatment of "mental disorders" 26, 27 (Wilcoxon 267
Location Shift = 0.711-0.945 for "kinase inhibitors" and select cancer types, 268
Location Shift = 0. 882 for "dopamine antagonists" and "mental disorders", p-269 value < 0.001, Figure S9 ). In fact, almost all drug class-disease associations 270 contained at least one FDA-approved drug for the respective disease, giving us 271 added confidence in our model. Of note, each drug was allowed to be 272 categorized into numerous drug classes, leading to unexpected, yet easily 273 explained, results; for example, "dopamine antagonists" appearing as a top drug 274 class for "neurological diseases". This is due to risperidone, a drug traditionally 275 used for schizophrenia and mood disorders, also having a secondary indication 276 of Alzheimer's type severe dementia. 277 278 Next, we further interrogated the drug classes associated with "neurological 279 diseases" and "diabetes", specifically. CATNIP scores were able to correctly 280 identify almost all drug classes known to treat these diseases (Figure 3A-B) . To 281 identify possible repurposing candidates, we focused our attention on drug 282 classes shown to have a large positive effect size with this CATNIP analysis but 283 are not currently approved for treatment. For "neurological diseases", the use of 284 adrenergic uptake inhibitors, traditionally used as antidepressants, was the top 285 repurposing candidate ( Figure 3A) . For "diabetes" alpha 1 antagonists and 286 kinase inhibitors were identified as possible novel treatments for diabetes 287 (Figure 3B) . We believe further investigation into these drug classes and 288 diseases could lead to successful clinical applications. 289
290
CATNIP interpretability reveals reasoning for repurposing candidates 291
From our list of repurposing candidates, we chose two novel drug class-disease 292 associations to further investigate. 293 294 Adrenergic uptake inhibitors applied to Parkinson's disease 295 296 First, we evaluated the relationship between "neurological diseases" and 297 "adrenergic uptake inhibitors". We focused on the drug pairs with the highest 298 CATNIP scores, i.e. those predicted with the highest confidence to share at least 299 one indication (Figure 3C) . Of all the adrenergic uptake inhibitors, we found that 300 amitriptyline and trimipramine, two anti-depressants, had the highest CATNIP 301 scores with the "neurological diseases" drugs. The drugs that shared the 302 strongest connections with amitriptyline and trimipramine were drugs approved 303
for Parkinson's disease (PD). Specifically, metixene, atropine, pergolide and 304 benzatropine were associated with amitriptyline, according to CATNIP, and 305 trimipramine was associated to benzatropine and rotigotine. Trimipramine was 306 also strongly connected with orphenadrine, which is sometimes used off label in 307
PD, but will not be included in the following analyses. 308 309 Using the CATNIP model, we evaluated which features contributed towards the 310 prediction of amitriptyline and trimipramine to share an indication with PD drugs. 311
We found that target, gene ontology, and pathway similarity all strongly 312 contributed to the predictions for both amitriptyline and trimipramine (Figure 3D , 313 Figure S10). Since target similarity and distance between targets (in a protein-314 protein interaction network) were among the top contributing features, we 315 investigated which gene targets were shared amongst these drug pairs. We 316 found that amitriptyline targets three specific gene classes that are also targeted 317 by at least one of the PD drugs: muscarinic acetylcholine receptors, G-coupled 318 protein receptors (GPCRs), and alpha adrenergic receptor. Trimipramine also 319 targets muscarinic acetylcholine receptors, alpha-adrenergic receptors, and 320 dopamine transporters, which is similar to benzatropine, a PD drug. All these 321 receptors have well-defined relationships with PD and other neurological 322 diseases 25, 28, 29 , which adds support for repurposing amitriptyline and/or 323
trimipramine. 324
Amitriptyline may be an ideal candidate for use in PD patients. We evaluated the 326 shared molecular function gene ontology terms shared between amitriptyline and 327 all four PD drugs. GPCR activity was once again identified (Supplementary 328 Data). We then interrogated the biological pathways these drug targets are 329 involved in and found many broad GPCR pathways overlapping between 330 amitriptyline and the PD drugs (Figure S11) including the Reactome pathway 331 "GASTRIN_CREB_SIGNALLING PATHWAY VIA PKC AND MAPK". Several 332 recent studies support the link between gastrin-releasing peptide signaling to 333 brain function 30 . Through CATNIP, we have identified "adrenergic uptake 334
inhibitors" like amitriptyline and trimipramine as a possible treatment for PD. 335 336
Kinase inhibitors applied to Diabetes 337
Our CATNIP analysis identified an opportunity to repurpose "kinase inhibitors" for 338 the treatment of diabetes (Figure 3B) . Of the drug pairs evaluated in this context, 339 the link between vandetanib, a thyroid cancer drug, and gliclazide, a Type 2 340 diabetes drug (CATNIP Score = 6.39, Figure 3E ) was the strongest. This identifying, and repurposing predictions based on system-wide drug scopes. 360
361
The CATNIP method allows for broad-scale drug repurposing opportunities to be 362 readily identified. By identifying and interpreting our drug similarity features, we 363 can investigate the possible mechanisms behind these repurposing candidates. 364
The benefit of using drug similarity features is two-fold. First, these features are 365 readily available for both approved and investigational drugs, which have been 366 underserved by previous repurposing methods. Second, the interpretability of the 367 features allows us to identify possible mechanisms of action when we back 368 engineer what contributed to high CATNIP scores. 369
370
We found strong support for repurposing amitriptyline and trimipramine, both of 371 which are in clinical use as anti-depressants, for PD. These drugs have many 372 functions in addition to being adrenergic uptake inhibitors, such as serotonin 373 blockers, anticholinergics, and the mechanisms overlapping with current PD 374 drugs described above. Movement Disorders Society guidelines found 375 insufficient evidence to support the use of amitriptyline for depression in PD 31 376 and a published Practice Parameter found only level C evidence for its use 32 . 377
However, amitriptyline has been commonly used for not only depression but 378 other off-label indications in neurological disorders, including pain 33 . While clinical 379 trials have been conducted for the effect of amitriptyline on depression in PD 380 patients 34 , currently there are no trials evaluating amitriptyline or trimipramine as 381 a treatment for other symptoms and signs of PD. There have, however, been 382 preclinical studies evaluating amitriptyline as a potential therapy for PD. In rodent 383 models of PD, amitriptyline affects levels of neurotrophic factors including 384 BDNF 35 and decreases dopamine cell loss in these models 36, 37 . It has been 385 suggested to mitigate microglial inflammation 38 . Moreover, with the suggestion 386 that amitriptyline may have shorter term symptomatic motor benefit, it may 387 enhance levodopa efficacy 39 . 388
389
When we more closely evaluated trimipramine, we found compelling evidence 390 this could be a potential PD therapeutic. Specifically, the targets of trimipramine 391 make it a potentially strong therapeutic to combat loss of motor function amongst 392 PD patients. This benefit is due to the dual targeting of DRD2 and alpha 2 393 adrenergic receptors, which is similar to piribedil, an investigational PD 394 medication that was not included within our final CATNIP network due to a lack of 395 available information. In a review of piribedil, it was highlighted that the agonistic 396 D2/D3 activity combined with alpha 2 adrenergic antagonism can lead to 397 preservation of motor function 40 . However, further research must be done to 398 better understand the exact effects that trimipramine has on both dopamine and 399 alpha 2 adrenergic receptors. Further research into trimipramine could quickly 400 lead to a clinical trial for PD patients with specific motor function end points. 401
402
We also identified a repurposing opportunity with kinase inhibitors for the 403 treatment of diabetes, due to the strong predicted connection between 404 vandetanib, a thyroid cancer drug, and gliclazide. While there have been some 405 preclinical animal studies investigating the use of kinase inhibitors in diabetes 41, 406 42 , to our knowledge, there has yet to be an approved kinase inhibitor for the 407 treatment of diabetes. Both vandetanib and gliclazide are known to target 408 VEGFA, which has shown a clear connection to diabetes pathology 43 Besides the targeting of VEGFA/VEGFR1, vandetanib's target EGFR can also 417 potentially help diabetes pathology. Inflammatory cytokines (including, but not 418 limited to, IL-8 and TNF-α) have been shown to be associated with the 419 progression of diabetic neuropathy 48 . The inhibition of EGFR through the use of a 420 kinase inhibitor in past work has reduced the expression of both to IL-8 and TNF-421 α in rats 49 . Therefore, we believe vandetanib could be considered as a potential 422 diabetes treatment, due to its ability to target EGFR leading to a possible 423 decrease in inflammatory cytokine production. 424
425
In addition to the exciting predicted repurposing opportunities we have chosen to 426 highlight, many other drug classes showed significant repurposing potential for 427 mental disorders, neurological diseases, and several different cancer types. 428
While diving into each of these opportunities is outside the scope of this paper, 429
we hope that researchers take it upon themselves to further investigate these 430 candidate drug class-disease associations. 431
432
It is important to acknowledge certain limitations to CATNIP, such as data 433 availability and the application to rare diseases. Although this model does not 434 rely on disease similarity information, it does require known molecular target 435 information to obtain peak predictive power. This target information can 436 frequently be unavailable for early stage compounds. Additionally, this method 437 would have limited use when searching for drugs to be repurposed for diseases 438 with very few or no clinically approved compounds. MetaMap has previously been shown to successfully exceeded human mapping 459 capabilities 14 . Using a custom Python script we identified synonym candidate to 460 further improve indication semantics. A random subset of the indications were 461 manually reviewed and found to correctly map to standardized terms with a 95% 462 accuracy (Figure S1B) . We then filtered our list of drugs to the 2576 drugs that 463 shared at least one indication with another drug. Correlation, Jaccard Index, and Dice Similarity. In cases where there was 475 insufficient or missing information, features were imputed by using the median 476 value for that feature in drug pairs with complete information. 477
Network Features 479
We curated a biological network that contains 22,399 protein-coding genes, 480 6,679 drugs, and 170 TFs. The protein-protein interactions represent established 481 interaction 53-55 , which include both physical (protein-protein) and non-physical 482 (phosphorylation, metabolic, signaling, and regulatory) interactions. The drug-483 protein interactions were curated from several drug target databases 55 . 484 485
Statistical Analysis 486
For each similarity feature, a Kolmogorov-Smirnov (KS) test was performed 487 between the set of drug pairs that shared an indication and those that did not 488 share an indication. The KS test was chosen to identify non-linear predictive 489
power. In addition, the Pearson correlation between all numeric features was 490 calculated. These tests were performed using custom scripts in R statistical 491 software 56 . 492 493
Model Building 494
We trained a two-class classifier predictive model using the features described 495 above. Our classes were determined as a binary of "shared" or "non-shared" 496 indication. Drugs were only included if they shared an indication with at least one 497 other drug. A 5-fold cross-validation gradient boosting model was used after 498 careful model selection and implemented using the XGBoost package 57 within 499 the R statistical software. Additional models that were tested and compared 500 using the AUC and AUPRC of 5-fold cross-validation were: Support Vector 501
Machine with a radial kernel model, logistic regression with elastic net and 502 logistic regression with lasso, all using custom R scripts. A custom-made R script 503 was used to implement a grid-search to optimize the hyperparameters of our 504 model. Our model objective was a logistic regression for binary classification and 505
we output a score pre-logistic transformation. The class size of "shared" vs. "non-506
shared" was imbalanced, therefore we applied downsampling to each fold of 
Network Construction 520
We constructed a drug similarity network based upon our classifier results with 521 drugs as nodes and our raw model output as the edge weight. This network was 522 visualized using the visNetwork package 61 and used in analyses using the iGraph 523 package 62 within R 56 . 524
525
ATC Repurposing Analysis 526
The Anatomical Therapeutic Chemical (ATC) code for all drugs were found in 527
DrugBank 50 , and the highest level code was assigned. Drugs with multiple ATC 528 codes assigned to them were re-assigned into the category "Various". A circular 529
repurposing network was created with ATC codes as the nodes using the 530 iGraph 62 and gGraph 63 packages with R 56 . The graph edge weights were based 531 on the mean classifier output between all drugs of each ATC code category. To 532 reduce noise within the repurposing network an initial cut-off of drug pairs with a 533 classifier output of 7.4 and above was implemented, leaving 792 drug pairs to 534 examine. Manual literature searches were used to validate repurposing 535 opportunities. 536 537
Drug Class Repurposing Analysis 538
Drug classes for all drugs were found in DrugBank 50 and were filtered to include 539 only "inhibitor", "antagonist," and "agonist" classes that had at least 20 drugs, to 540 ensure enough statistical power. Additionally, we identified four main disease 541 areas of interest: "mental disorders", "neurological diseases", "diabetes", and 542 "cancer". The UMLS 13 sematic codes "modb" and "neop" were used to identify 543 indications falling within mental disorders and cancer, respectively. Cancer was 544 further refined into different cancer types based on a keyword search in a custom 545 Python script. All UMLS concept IDs containing the word "diabetes" were 546 included within the diabetes category. For "neurological diseases", we refined our 547 list to only include Parkinson's Disease, Alzheimer's, Epilepsy, and Dementia, to 548 balance both specificity in disease type and enough drugs to make statistically 549 sufficient sample size. The effect of each feature on the CATNIP score for specific drug pairs was found 563 by iteratively changing the feature value to the median value of that feature for all 564 drug pairs. Since the clear majority of all drug pairs do not share an indication 565 this is the best approximate for that feature having no contribution to the CATNIP 566 score. The difference in the new CATNIP score and the correct CATNIP score 567 was then measured. Cancer, E) Pancreatic Cancer, F) Bone Cancer, G) Oesophagus Cancer, H) 896
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and those that do not. 906 907 Figure S10 : Target features drive the prediction of trimipramine as a Parkinson's 908
Disease treatment. A) The decrease in the CATNIP score when removing each 909 feature for trimipramine and select Parkinson's Disease drugs. 910 911 Figure S11 : Many pathways or gene ontology groups overlap, fueling CATNIP 912
predictions. The overlap between amitriptyline and select Parkinson's Disease 913 drugs for A) reactome pathways, B) KEGG pathways, and D) molecular function 914 gene ontologies. The overlap between vandetanib and gliclazide for A) reactome 915 pathways, B) KEGG pathways, and D) molecular function gene ontologies. 916 917
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